ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2022, Vol. 31 ›› Issue (1): 84-89.DOI: 10.3969/j.issn.1006-298X.2022.01.017

• • 上一篇    下一篇

血管紧张素Ⅱ治疗血管扩张性休克

  

  • 出版日期:2022-02-28 发布日期:2022-02-18

Angiotensin Ⅱ in vasodilatory shock

  • Online:2022-02-28 Published:2022-02-18

摘要: 血管扩张性休克以广泛性血管扩张为特点,难治性血管扩张性休克患者需要大剂量血管活性药物维持血压,死亡率高。过量使用儿茶酚胺类升压药可造成内脏缺血、心律失常等严重不良后果。基于Ⅲ期临床试验等研究结果,美国食品与药品管理局批准血管紧张素Ⅱ用于治疗血管扩张性休克。本文对血管紧张素Ⅱ治疗血管扩张性休克的研究进展作一综述。


关键词: 血管紧张素Ⅱ,血管扩张性休克,脓毒性休克,升压药

Abstract: Vasodilatory shock is a type of shock characterized by extensive vasodilation. Patients with refractory vasodilatory shock who require large doses of vasoactive drugs to maintain blood pressure, resulting a high mortality rate. Excessive use of catecholamines will bring visceral ischemia, arrhythmia and other serious adverse consequences. The US Food and Drug Administration approved angiotensin Ⅱ for the treatment of vasodilatory shock based on the results of studies including a Phase Ⅲ clinical trial. This article reviews recent advances of angiotensin Ⅱ in vasodilatory shock.


Key words: angiotensin Ⅱ, vasodilatory shock, septic shock, vasopressors